AR005827A1 - Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion - Google Patents
Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacionInfo
- Publication number
- AR005827A1 AR005827A1 ARP970100594A ARP970100594A AR005827A1 AR 005827 A1 AR005827 A1 AR 005827A1 AR P970100594 A ARP970100594 A AR P970100594A AR P970100594 A ARP970100594 A AR P970100594A AR 005827 A1 AR005827 A1 AR 005827A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- aciclic
- nucleosides
- understands
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- -1 isoleucyl ester Chemical group 0.000 abstract 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- 125000002114 valyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de la fórmula (I), donde uno de R1 y R2 es un éster de valilo o isoleucilo, el otro R1 y R2 es un alquilo -C(=O)C3-C21, saturado omonoinsaturado, opcionalmente sustituido y R3 es OH o H; y las sales farmacéuticamenteaceptables , y un compuesto de fórmula (II) comointermediario, que comprende R1 y R2 que son: i) -C(O)CH(CH(CH3)2)NH2 o -C(O)CH(CH(CH3)CH2CH3)NH2, opcionalmente N protegidos; ii) un alquilo-C(=O)C3-21 saturado o monoinsaturado, opcionalmentesustituido o iii) un grupo de protección regioselectiva y el otro R1 y R2 es hidrógeno o ambos R1y R2 son i) o ambos ii) como se ha definido arriba. Resultan útiles puesto que mejoran la biodisponibilidad de los antivirales contrainfeccionescausadas por herpes o retrovirus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600613A SE9600613D0 (sv) | 1996-02-16 | 1996-02-16 | Acyclic nucleoside derivatives |
| SE9600614A SE9600614D0 (sv) | 1996-02-16 | 1996-02-16 | Antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005827A1 true AR005827A1 (es) | 1999-07-14 |
Family
ID=26662518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100594A AR005827A1 (es) | 1996-02-16 | 1997-02-14 | Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US5869493A (es) |
| EP (2) | EP0888348B1 (es) |
| JP (2) | JP4171069B2 (es) |
| KR (1) | KR100464692B1 (es) |
| CN (1) | CN1067073C (es) |
| AR (1) | AR005827A1 (es) |
| AT (2) | ATE231507T1 (es) |
| AU (1) | AU715062B2 (es) |
| BG (1) | BG64179B1 (es) |
| CA (1) | CA2243826C (es) |
| CZ (1) | CZ292169B6 (es) |
| DE (2) | DE69718619T2 (es) |
| DK (1) | DK0888348T3 (es) |
| EA (2) | EA001404B1 (es) |
| ES (2) | ES2189942T3 (es) |
| HU (1) | HU229865B1 (es) |
| IL (1) | IL124760A (es) |
| MY (1) | MY123083A (es) |
| NO (1) | NO322930B1 (es) |
| NZ (1) | NZ330472A (es) |
| PL (1) | PL184892B1 (es) |
| SK (1) | SK284613B6 (es) |
| TR (1) | TR199801318T2 (es) |
| TW (1) | TW533213B (es) |
| WO (2) | WO1997030052A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458772B1 (en) * | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
| US6703394B2 (en) | 1996-02-16 | 2004-03-09 | Medivir Ab | Acyclic nucleoside derivatives |
| US5869493A (en) | 1996-02-16 | 1999-02-09 | Medivir Ab | Acyclic nucleoside derivatives |
| AU735438B2 (en) * | 1996-11-12 | 2001-07-05 | Medivir Ab | Nucleosides |
| CA2572577C (en) * | 1997-02-10 | 2011-04-05 | Medivir Ab | Synthesis of acyclic nucleoside derivatives |
| US6184376B1 (en) * | 1997-02-10 | 2001-02-06 | Mediver Ab | Synthesis of acyclic nucleoside derivatives |
| IL134503A0 (en) * | 1997-08-15 | 2001-04-30 | Medivir Ab | Nucleoside analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv) |
| AU1711599A (en) * | 1997-12-19 | 1999-07-12 | Bristol-Myers Squibb Company | Prodrugs of lobucavir and methods of use |
| EP1511750A1 (en) * | 2003-04-30 | 2005-03-09 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of famciclovir |
| BRPI0519306A2 (pt) | 2004-12-30 | 2009-01-06 | Medivir Ab | compostos éteis no tratamento de hiv |
| WO2006082588A2 (en) * | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
| CN101033238B (zh) * | 2006-03-06 | 2011-02-16 | 中国科学院上海药物研究所 | 嘌呤类化合物双氨基酸酯的制备方法和用途 |
| ZA200702234B (en) * | 2006-03-21 | 2008-07-30 | Cipla Ltd | Preparation of ester of purine derivatives |
| MX2010000424A (es) | 2007-07-09 | 2010-08-10 | Easter Virginia Medical School | Derivados de nucleosidos sustituidos con propiedades antivirales y antimicrobianas. |
| CN101827846B (zh) | 2007-09-21 | 2012-08-15 | 伊皮芬尼生物科学公司 | 伐马洛韦多形体 |
| WO2011022712A1 (en) * | 2009-08-21 | 2011-02-24 | Epiphany Biosciences, Inc. | Method of treating infectious mononucleosis with acylic nucleoside derivatives |
| RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
| KR101763127B1 (ko) | 2015-06-23 | 2017-08-01 | (주)농협아그로 | 끈끈이 엠보싱 트랩 테이프 |
| WO2024118480A1 (en) * | 2022-11-28 | 2024-06-06 | Epiphany Biosciences | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| FR2040177A1 (en) | 1969-01-31 | 1971-01-22 | Robugen Gmbh | 2-deoxyribosyl-uracil derivs |
| US3817982A (en) | 1971-12-29 | 1974-06-18 | Syntex Inc | 2{40 ,3{40 -unsaturated nucleosides and method of making |
| US4247544A (en) | 1979-07-02 | 1981-01-27 | The Regents Of The University Of California | C-5 Substituted uracil nucleosides |
| US4267171A (en) | 1979-07-02 | 1981-05-12 | The Regents Of The University Of California | C-5 Substituted cytosine nucleosides |
| JPS57146798A (en) | 1981-03-06 | 1982-09-10 | Yamasa Shoyu Co Ltd | Hexosyl nucleoside derivative |
| NL8202626A (nl) * | 1982-06-29 | 1984-01-16 | Stichting Rega V Z W | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
| IL73682A (en) * | 1983-12-20 | 1991-08-16 | Medivir Ab | Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation |
| SE8406538D0 (sv) * | 1984-12-21 | 1984-12-21 | Astra Laekemedel Ab | Novel derivatives of purine |
| US4724232A (en) | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| EP0286825A3 (en) | 1987-03-18 | 1989-04-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections |
| SE8701605D0 (sv) | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| EP0339075B1 (en) * | 1987-10-28 | 1993-08-18 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
| SE8704298D0 (sv) | 1987-11-03 | 1987-11-03 | Astra Ab | Compounds for use in therapy |
| SE8801729D0 (sv) | 1988-05-06 | 1988-05-06 | Astra Ab | Purine derivatives for use in therapy |
| US5284837A (en) | 1988-05-06 | 1994-02-08 | Medivir Ab | Derivatives of purine, process for their preparation and a pharmaceutical preparation |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| SE8802173D0 (sv) | 1988-06-10 | 1988-06-10 | Astra Ab | Pyrimidine derivatives |
| ATE123285T1 (de) * | 1988-12-19 | 1995-06-15 | Wellcome Found | Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate. |
| FI95384C (fi) | 1989-04-06 | 1996-01-25 | Squibb Bristol Myers Co | Menetelmä 3'-deoksi-3'-substituoitujen metyylinukleosidien valmistamiseksi ja menetelmässä käytettäviä välituotteita |
| US5216142A (en) * | 1989-04-17 | 1993-06-01 | Efamol Holdings Plc | Anti-virals |
| US5674869A (en) * | 1990-07-07 | 1997-10-07 | Beecham Group Plc | Pharmaceutical treatment |
| SE9003151D0 (sv) | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
| GB2260319B (en) * | 1991-10-07 | 1995-12-06 | Norsk Hydro As | Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity |
| US5874578A (en) | 1992-07-13 | 1999-02-23 | Bristol-Myers Squibb | Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process |
| GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| DE4311801A1 (de) * | 1993-04-09 | 1994-10-13 | Hoechst Ag | Neue Carbonsäureester von 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purin, deren Herstellung sowie deren Verwendung |
| GB9320316D0 (en) * | 1993-10-01 | 1993-11-17 | Smithkline Beecham Plc | Pharmaceuticals |
| TW282470B (es) * | 1993-11-18 | 1996-08-01 | Ajinomoto Kk | |
| US5521161A (en) | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
| WO1995022330A1 (en) * | 1994-02-17 | 1995-08-24 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| PE32296A1 (es) * | 1994-07-28 | 1996-08-07 | Hoffmann La Roche | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables |
| US5543414A (en) * | 1994-07-28 | 1996-08-06 | Syntex (Usa) Inc. | Achiral amino acid acyl esters of ganciclovir and its derivatives |
| JP3906488B2 (ja) | 1995-02-21 | 2007-04-18 | 味の素株式会社 | プリン誘導体の製造方法 |
| CN1064683C (zh) * | 1996-01-26 | 2001-04-18 | 弗·哈夫曼-拉罗切有限公司 | 制备嘌呤衍生物的方法 |
| US5700936A (en) * | 1996-01-26 | 1997-12-23 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate |
| AU1592897A (en) * | 1996-01-26 | 1997-08-20 | F. Hoffmann-La Roche Ag | Process for preparing purine derivatives |
| US5756736A (en) * | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| US5840890A (en) * | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| US5869493A (en) | 1996-02-16 | 1999-02-09 | Medivir Ab | Acyclic nucleoside derivatives |
| US6703394B2 (en) * | 1996-02-16 | 2004-03-09 | Medivir Ab | Acyclic nucleoside derivatives |
| EP0827960A1 (en) | 1996-09-10 | 1998-03-11 | Ajinomoto Co., Inc. | Process for producing purine derivatives |
-
1997
- 1997-02-10 US US08/798,216 patent/US5869493A/en not_active Expired - Lifetime
- 1997-02-14 EP EP97903708A patent/EP0888348B1/en not_active Expired - Lifetime
- 1997-02-14 EA EA199800729A patent/EA001404B1/ru not_active IP Right Cessation
- 1997-02-14 EA EA200000787A patent/EA002809B1/ru not_active IP Right Cessation
- 1997-02-14 JP JP52927997A patent/JP4171069B2/ja not_active Expired - Fee Related
- 1997-02-14 NZ NZ330472A patent/NZ330472A/en not_active IP Right Cessation
- 1997-02-14 AT AT97903709T patent/ATE231507T1/de not_active IP Right Cessation
- 1997-02-14 IL IL12476097A patent/IL124760A/xx not_active IP Right Cessation
- 1997-02-14 DK DK97903708T patent/DK0888348T3/da active
- 1997-02-14 TR TR1998/01318T patent/TR199801318T2/xx unknown
- 1997-02-14 DE DE69718619T patent/DE69718619T2/de not_active Expired - Lifetime
- 1997-02-14 AR ARP970100594A patent/AR005827A1/es active IP Right Grant
- 1997-02-14 ES ES97903709T patent/ES2189942T3/es not_active Expired - Lifetime
- 1997-02-14 WO PCT/SE1997/000242 patent/WO1997030052A1/en not_active Ceased
- 1997-02-14 ES ES97903708T patent/ES2189941T3/es not_active Expired - Lifetime
- 1997-02-14 DE DE69718626T patent/DE69718626T2/de not_active Expired - Lifetime
- 1997-02-14 AT AT97903708T patent/ATE231508T1/de active
- 1997-02-14 PL PL97328335A patent/PL184892B1/pl unknown
- 1997-02-14 KR KR10-1998-0706309A patent/KR100464692B1/ko not_active Expired - Fee Related
- 1997-02-14 TW TW086101758A patent/TW533213B/zh not_active IP Right Cessation
- 1997-02-14 HU HU9900680A patent/HU229865B1/hu not_active IP Right Cessation
- 1997-02-14 CA CA002243826A patent/CA2243826C/en not_active Expired - Fee Related
- 1997-02-14 CZ CZ19982322A patent/CZ292169B6/cs not_active IP Right Cessation
- 1997-02-14 AU AU18182/97A patent/AU715062B2/en not_active Ceased
- 1997-02-14 EP EP97903709A patent/EP0880521B1/en not_active Expired - Lifetime
- 1997-02-14 WO PCT/SE1997/000241 patent/WO1997030051A1/en not_active Ceased
- 1997-02-14 JP JP9529280A patent/JP2000504721A/ja not_active Ceased
- 1997-02-14 SK SK985-98A patent/SK284613B6/sk not_active IP Right Cessation
- 1997-02-14 MY MYPI97000553A patent/MY123083A/en unknown
- 1997-02-14 CN CN97192183A patent/CN1067073C/zh not_active Expired - Fee Related
-
1998
- 1998-07-13 NO NO19983216A patent/NO322930B1/no not_active IP Right Cessation
- 1998-07-22 BG BG102647A patent/BG64179B1/bg unknown
- 1998-09-03 US US09/146,194 patent/US6255312B1/en not_active Expired - Lifetime
-
2000
- 2000-04-17 US US09/550,554 patent/US6576763B1/en not_active Expired - Fee Related
-
2008
- 2008-10-03 US US12/245,553 patent/US8124609B2/en not_active Expired - Fee Related
-
2012
- 2012-01-20 US US13/355,231 patent/US20120123119A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR005827A1 (es) | Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion | |
| PA8494101A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| AR023275A1 (es) | Derivados de la purina | |
| ES2131106T3 (es) | Compuestos de benzotiazepina hipolipidemicos. | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| HUT62886A (en) | Process for producing new, furyl and thienyl group-substituted taxane derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| AR020032A1 (es) | Derivados de 1,3 -metil eritromicina. | |
| AR026052A1 (es) | Derivados de purina | |
| CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
| MX9304579A (es) | Derivados de 4-aza-5alfa-androstan-3-ona 17beta-substituidos, fluorados, proceso para su preparaciony composicion farmaceutica que los comprende. | |
| ES2179996T3 (es) | Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos. | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| AR012436A1 (es) | Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion. | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| PA8444901A1 (es) | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios | |
| ES2192263T3 (es) | Derivados de benzo(c)quinolizina, su preparacion y empleo como inhibidores de 5-alfa-reductasas. | |
| AR027454A1 (es) | Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos | |
| HUP0303020A2 (hu) | Androgén 7-szubsztituált 11-halogénezett szteroidok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
| PA8474401A1 (es) | 3-ceto derivados triciclicos de 6-0-metileritromicina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |